Delaware 2025-2026 Regular Session

Delaware Senate Bill SB101

Introduced
4/9/25  
Introduced
5/6/25  
Refer
4/9/25  
Engrossed
5/13/25  

Caption

An Act To Amend Title 16 Of The Delaware Code Relating To The Definition Of The Patient-practitioner Relationship.

Impact

The bill is expected to have a significant effect on how patients with OUD receive care in Delaware, particularly expanding access to essential medications through telehealth services. By modernizing the definition of the patient-practitioner relationship, SB101 removes barriers that restricted telemedicine's use in prescribing controlled substances. The new legislation is positioned to enhance the state's public health response to the opioid crisis by facilitating timely and efficient access to treatment for individuals who may otherwise face barriers to care.

Summary

Senate Bill 101 aims to amend Title 16 of the Delaware Code by clarifying the definition of the patient-practitioner relationship in light of telehealth regulations, particularly regarding the treatment of opioid use disorder (OUD). The bill seeks to align the Uniform Controlled Substances Act, which traditionally mandates an in-person examination before prescription, with Delaware's Telehealth Access Act, which permits treatment without such an exam. This harmonization allows practitioners to prescribe Schedule III through V medications for OUD via telemedicine, provided specific criteria are met.

Sentiment

The sentiment surrounding SB101 appears to be generally supportive, particularly among healthcare providers and advocates for equitable access to treatment. Proponents argue that this bill represents a crucial step towards addressing the opioid epidemic by utilizing telehealth as a vital tool for expanding treatment accessibility. However, there are concerns among certain stakeholders regarding the implications of reducing the necessity for in-person consultations, with critics cautioning about the potential for oversight issues in patient care.

Contention

Notable points of contention revolve around the balance between improving access to necessary medications for OUD and ensuring the integrity of patient care through thorough evaluation. Critics of the bill might argue that the absence of in-person examinations could lead to inadequate assessments of patient needs and the individual circumstances that may not be fully addressed in a remote consultation. This debate encapsulates broader discussions about the role of telemedicine in modern healthcare, particularly in sensitive areas such as addiction treatment.

Companion Bills

No companion bills found.

Similar Bills

NH SB390

Relative to telemedicine and telehealth.

VA HB1787

Schedule VI controlled substance; practitioner-patient relationship.

VA SB1084

Prescription of Schedule VI controlled substances; asynchronous interactions.

VA HB921

Controlled substances; prescriber may establish practitioner-patient relationship.

VA HB921

Controlled substances; prescriber may establish practitioner-patient relationship.

NJ A2911

Requires practitioners to disclose business relationship with out-of-State facilities when making patient referrals to those facilities.

NJ A1069

Requires practitioners to disclose business relationship with out-of-State facilities when making patient referrals to those facilities.

VA HB1898

Optometry; TPA-Formulary; TPA-Formulary Committee; dissolution.